ArticleCurrent therapeutic research, clinical and experimental2026
Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database.
Article in Current therapeutic research, clinical and experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intravenous immunoglobulin (IVIg) therapies are widely used for replacement and immunomodulatory indications but are associated with known risks of adverse drug reactions (ADRs), underscoring the importance of long-term, product-specific safety surveillance. Objective: This analysis evaluated the long-term real-world safety profile of a 5% IVIg product approved for replacement therapy in primary and secondary immunodeficiencies and for immunomodulatory indications. Methods: Spontaneous post-marketing ADR reports for Kedrion 5% IVIg (January 1997-May 2025) were descriptively analyzed using the Kedrion Pharmacovigilance Database. ADRs were defined per regulatory criteria and summarized by frequency, seriousness, demographics, and estimated IVIg exposure. Results: An estimated 3,391,766 doses were distributed worldwide, with 2,500 ADRs reported in 958 individual cases, corresponding to an overall individual case reporting rate of 2.8 per 10,000 infusions. The most frequently reported ADRs were headache, pyrexia, vomiting, chills, nausea, and urticaria, with reporting rates ranging from 0.44 to 0.16 per 10,000 infusions. ADRs were predominantly non-serious. Individuals aged 40-64 years accounted for the highest proportion of reported and serious ADRs, followed by those aged 18-39 years and 65-74 years; distribution by sex generally mirrored age-group patterns. Annual reporting varied over time, with higher numbers of reports in recent years, while the overall nature of reported ADRs remained consistent. Conclusions: This analysis represents one of the largest and longest post-marketing pharmacovigilance evaluations of an individual IVIg product. Findings demonstrate stable long-term safety and an ADR profile consistent with clinical trial data and approved product labeling, supporting a favorable benefit-risk profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.